文献速递心力衰竭与心肌病冠心病心律失常

2型糖尿病患者心衰风险分层与SGLT2抑制剂疗效

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
PubMed 文献 · Circulation · 2019-08-31

本研究基于SAVOR-TIMI 53安慰剂组8212例T2DM患者开发心衰住院(HHF)临床风险评分,并在DECLARE-TIMI 58安慰剂组8578例中外部验证。5个变量构成0-7分评分,识别HHF风险>20倍梯度(C指数0.81和0.78)。达格列净相对风险降低相似(25%-34%),但绝对风险降低在高危组更大。

要点

  • 5变量评分(心衰史、房颤、冠心病、eGFR、UACR)可区分HHF风险>20倍。
  • 达格列净相对风险降低25%-34%跨风险评分相似。
  • 高危(2分)和极高危(≥3分)患者4年绝对风险降低1.5%和2.7%。

核心结论

  • 基于5变量构建的HHF临床风险评分可识别T2DM中HHF高风险患者,这些患者从SGLT2抑制剂获得的绝对获益更大。

研究设计与样本

  • 在SAVOR-TIMI 53安慰剂组8212例T2DM患者中开发HHF临床风险评分,候选变量经多变量Cox回归评估,P<0.001的独立指标纳入评分。
  • 在DECLARE-TIMI 58安慰剂组8578例T2DM患者中外部验证评分,并按基线HHF风险评估达格列净的相对和绝对风险降低。

主要发现

  • 5个独立预测变量:既往心衰、房颤史、冠心病、eGFR、尿白蛋白/肌酐比值。
  • 基于上述变量的0-7分整数评分在开发与验证队列中识别HHF风险>20倍梯度(趋势P<0.001),C指数分别为0.81和0.78。
  • 达格列净相对风险降低在各风险评分患者中相似(25%-34%)。
  • 绝对风险降低在高基线风险者更大(单侧趋势P=0.04),高危(2分)和极高危(≥3分)患者4年Kaplan-Meier估计HHF绝对风险降低分别为1.5%和2.7%。

关键数值与推荐

  • 风险评分变量:既往心衰、房颤史、冠心病、eGFR、尿白蛋白/肌酐比值,总分0-7分。
  • 高危定义为2分,极高危定义为≥3分。

临床怎么用

  • 可采用0-7分评分对T2DM患者进行HHF风险分层,评分≥2分者HHF风险较高。
  • 对评分高危和极高危患者,使用SGLT2抑制剂达格列净可获得更大的HHF绝对风险降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of developing heart failure. Sodium-glucose cotransporter-2 inhibitors reduce the risk of hospitalization for heart failure (HHF) in patients with T2DM. We aimed to develop and validate a practical clinical risk score for HHF in patients with T2DM and assess whether this score can identify high-risk patients with T2DM who have the greatest reduction in risk for HHF with a sodium-glucose cotransporter-2 inhibitor. METHODS: We developed a clinical risk score for HHF in 8212 patients with T2DM in the placebo arm of SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53). Candidate variables were assessed using multivariable Cox regression, and independent clinical risk indicators achieving statistical significance of P<0.001 were included in the risk score. We externally validated the score in 8578 patients with T2DM in the placebo arm of DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58). The relative and absolute risk reductions in HHF with the sodium-glucose cotransporter-2 inhibitor dapagliflozin were assessed by baseline HHF risk. RESULTS: Five clinical variables were independent risk predictors of HHF: prior heart failure, history of atrial fibrillation, coronary artery disease, estimated glomerular filtration rate, and urine albumin-to-creatinine ratio. A simple integer-based score (0-7 points) using these predictors identified a >20-fold gradient of HHF risk (P for trend <0.001) in both the derivation and validation cohorts, with C indices of 0.81 and 0.78, respectively. Although relative risk reductions with dapagliflozin were similar for patients across the risk scores (25%-34%), absolute risk reductions were greater in those at higher baseline risk (1-sided P for trend=0.04), with high-risk (2 points) and very-high-risk (≥3 points) patients having 1.5% and 2.7% absolute reductions in Kaplan-Meier estimates of HHF risk at 4 years, respectively. CONCLUSIONS: Risk stratification using a novel clinical risk score for HHF in patients with T2DM identifies patients at higher risk for HHF who derive greater absolute benefit from sodium-glucose cotransporter-2 inhibition. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01107886 and NCT01730534.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Berg DD, Wiviott SD, Scirica BM, et al. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019. PMID: 31474116. doi:10.1161/CIRCULATIONAHA.119.042685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。